Ovid Therapeutics Inc.
OVID- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001636651
Insider trades, last 90 days
None
- No open-market purchases or sales were filed in the last 90 days.
13F holders, Q2 2026
130
- +27 vs. Q1 2026
- Total value $395.55M
Superinvestors holding OVID
0
- None of the superinvestors held OVID at the end of Q2 2026.
Price chart
Latest insider trades
View all: Latest insider tradesOpen-market purchases and sales by OVID insiders, newest first.
| Filed (ET) | Trade date | Insider | Transaction | Shares | Avg price | Value | Shares after | Holding change | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Mar 2, 2026 | Feb 23, 2026 | ALEXANDER MARGARET A.President and CEO | SSaleCommon Stock | −11.66K | $1.45 | −$16.9K | 61.75K | −15.9% | SEC |
| Mar 2, 2026 | Feb 23, 2026 | Rona Jeffrey ACBFO | SSaleCommon Stock | −8.54K | $1.45 | −$12.38K | 88.19K | −8.8% | SEC |
| Dec 18, 2025 | Dec 11, 2025 | LEVIN JEREMY MCEO | PPurchaseCommon Stock · Derivative | +153.83K | – | – | 35.5K | – | SEC |
| Feb 28, 2025 | Feb 26, 2025 | ALEXANDER MARGARET A.President and COO | SSaleCommon Stock | −5.28K | $0.56 | −$2.96K | 73.41K | −6.7% | SEC |
| Feb 28, 2025 | Feb 26, 2025 | Rona Jeffrey ACBFO | SSaleCommon Stock | −3.9K | $0.56 | −$2.19K | 67.97K | −5.4% | SEC |
Top 5 13F holders, Q2 2026
View all: Top 5 13F holders, Q2 2026The largest institutional positions in OVID at the end of Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Jupiter Topco LLC | 20,741,234 | $55.9M | 0.02% | +20,741,234 | New |
| EVENTIDE ASSET MANAGEMENT, LLC | 11,812,241 | $31.77M | 0.42% | +1,895,330+19.1% | Added |
| BlackRock, Inc. | 10,823,480 | $29.12M | 0.00% | +9,290,197+605.9% | Added |
| RA CAPITAL MANAGEMENT, L.P. | 10,500,968 | $28.25M | 0.25% | −213,032−2.0% | Reduced |
| Affinity Asset Advisors, LLC | 10,144,562 | $27.29M | 1.33% | −491,756−4.6% | Reduced |